In addition, the FDA awarded an Orphan Products Development grant to support the evaluation of HyBryteTM for expanded treatment in patients with early-stage CTCL, including in the home use setting.
Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Conference Call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, ...